Severe malaria is a major contributor of deaths in African children up to five years of age. One valuable tool to support health workers in the management of diseases is clinical practice guidelines (CPGs) developed using robust methods. A critical assessment of the World Health Organization (WHO) and Kenyan paediatric malaria treatment guidelines with quinine was undertaken, with a focus on the quality of the evidence and transparency of the shift from evidence to recommendations.
Methods
Systematic reviews of the literature were conducted using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool to appraise included studies. The findings were used to evaluate the WHO and Kenyan recommendations for the management of severe childhood malaria.
Results
The WHO 2010 malaria guidance on severe malaria in children, which informed the Kenyan guidelines, only evaluated the evidence on one topic on paediatric care using the GRADE tool. Using the GRADE tool, this work explicitly demonstrated that despite the established use of quinine in the management of paediatric cases of severe malaria for decades, low or very low quality evidence of important outcomes, but not critical outcomes such as mortality, have informed national and international guidance on the paediatric quinine dosing, route of administration and adverse effects.
Conclusions
Despite the foreseeable shift to artesunate as the primary drug for treatment of severe childhood malaria, the findings reported here reflect that the particulars of quinine therapeutics for the management of severe malaria in African children have historically been a neglected research priority. This work supports the application of the GRADE tool to make transparent recommendations and to inform advocacy efforts for a greater research focus in priority areas in paediatric care in Africa and other low-income settings.
The online version of this article (doi:10.1186/1475-2875-10-201) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ME conceived of the topics for the systematic reviews. NM developed the methodology and conducted the reviews with assistance from NO. NM drafted the manuscript and ME and NO contributed to it. All authors read and approved the final manuscript.
Background
Severe falciparum malaria is a medical emergency. An estimated 800,000 annual deaths occur in African countries South of the Sahara as a direct result of malaria in children aged five years and less [1]. The Roll Back Malaria Partnership's goal is to control and ultimately eliminate malaria, which is consistent with the Millennium Development Goals (MDGs) 4, to reduce under-five child mortality, and 6 to reduce the incidence of infectious diseases including malaria. However, until achieved, appropriate treatment of severe malaria to prevent fatality and disability will be required. In spite of its narrow therapeutic window, which dictates careful dosing and monitoring, quinine has been the drug of choice for the treatment of severe malaria in Africa for over 30 years (and before that was in use since the 17th century). Exciting new results from an African multi-centre trial now suggest that artesunate should replace quinine as the first-line treatment [2]. In Kenya, however, changes are anticipated to take place progressively over the coming years as practical issues, such as making changes to national policy, procurement and supply chain issues and re-training of health workers, are tackled. In particular, the latter will demand a significant injection of funds from the national malaria control programme (Personal Communication, Dr Elizabeth Juma, Head of Division of Malaria Control, Ministry of Public Health and Sanitation). Meanwhile, quinine will inevitably remain the default treatment.
Best approaches to treatment are often encompassed in clinical practice guidelines (CPGs), tools to support health workers to make evidence-informed decisions in the management of their patients. Ideally CPGs combine the best available research gathered using standardized, robust, systematic methods and contextual factors, such as cost, feasibility, values, resources [3]. The World Health Organization (WHO), which is tasked with producing global clinical guidance, particularly for developing countries, has recently adopted one such transparent and systematic approach to developing its CPGs. This process applies the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool to transparently assess the quality of research evidence and develop recommendations [4]. The GRADE approach has rapidly become widely used in full or in part, and is endorsed or used by organizations including WHO, the UK's National Institute for Health and Clinical Excellence (NICE), the Scottish Intercollegiate Guidelines Network (SIGN), and the Cochrane Collaboration [5].
Anzeige
In March 2010, the WHO revised its malaria treatment guidance as a framework for country-level policy makers to adapt. For the first time, it incorporated the GRADE approach [6]. In Kenya, the Division of Malaria Control (DoMC) took the opportunity to revise its national guidelines for treatment of severe malaria in children, making them consistent with the 2010 WHO Malaria treatment guidelines (Table 1). In so doing, it changed Kenya's recommended quinine regimen from one that had been disseminated and promoted for over 10 years. Specific changes were an increase in the loading dose and maintenance doses of quinine. This policy change coincided with efforts by researchers, the Kenyan Ministry of Medical Services and others to update CPGs for management of 12 key paediatric conditions, including malaria [7], an approach also attempting to employ the GRADE tool [8]. However, as the 2010 WHO guidance did not employ the GRADE approach to systematically appraise the evidence available to inform the optimum use of quinine in African children, a series of systematic reviews were conducted to examine the quality of evidence available to help guide use of quinine in this population using the GRADE approach. This work demonstrates how treatment of severe malaria has largely been neglected by the research community. Further, it demonstrates how the GRADE tool helps make this explicit, pointing to its potential value for highlighting failures to invest in research on neglected diseases or populations.
Table 1
Summary of World Health Organization (2010) and Government of Kenya (2005 and 2010) clinical practice guidelines for the management of children with severe malaria
Treatment for children aged < 5 years with a diagnosis of severe malaria
GoK 2005
Basic Paediatric Protocols*
GoK 2010 Malaria Case Management Guidelines
WHO 2010 Malaria Case Management Guidelines
Pre-referral quinine loading dose
15 mg/kg IM injection
20 mg/kg IM injection
20 mg/kg IM injection
First-line treatment with quinine dose
15 mg/kg loading dose then 10 mg/kg every 12 hours by IV infusion or divided IM injection
20 mg/kg loading dose then 10 mg/kg every 8 hours by IV infusion or divided IM injection
20 mg/kg loading dose then 10 mg/kg every 8 hours by IV infusion or
divided IM injection
*Based on 1998 DoMC Malaria Treatment Guidelines.
Methods
Key clinical questions to be tackled in a series of systematic reviews that addressed the themes of effectiveness and safety of quinine for the treatment of Kenyan children with severe malaria were identified. These were:
1) Systematic review 1: Is there a value in administration of a loading dose of quinine in African children with severe malaria?
2) Systematic review 2: Should Kenya change its recommendation for treatment of severe malaria in children under 5 of 15 mg/kg loading dose followed by 10 mg/kg every 12 hours and replace it with the WHO recommended regimen of 20 mg/kg loading dose followed by 10 mg/kg every 8 hours?
Anzeige
3) Systematic review 3: What are the pharmacokinetics and effectiveness of IV-administered quinine compared to IM-administered quinine in African children with severe malaria?
4) Systematic review 4: Is there a link between IV-administered quinine and risk of hypoglycaemia in African children with severe malaria?
The clinical questions were developed in a PICO (Population, Intervention, Control/Comparator, Outcome) format and literature searches conducted in PubMed and the Cochrane Library (up to September 2010) using MeSH (Medical Subject Headings) search terms derived from PubMed. Free text searches with no language or time limitations were conducted. Additional searches were also conducted in PubMed using the clinical queries filter tool. Furthermore, bibliographies in the WHO guidelines and abstracts of the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference (2-6 November 2009, Nairobi, Kenya) were scanned. In a first round, identified manuscript titles were independently screened by two investigators (NM, ME) using pre-defined inclusion/exclusion criteria (Table 2). In a second round of screening, abstracts and full texts were read to select relevant studies to be included in the systematic reviews. Data from included studies were extracted into an in-house data extraction tool. Quinine doses were uniformly presented in the salt form as quinine sulphate. The GRADE tool was then used to critically appraise the quality of each study and following that, the quality of all available evidence informing a particular question/outcome combination was categorized based on GRADE guidelines (Table 3). Where no evidence of heterogeneity was found, binary outcome data from multiple studies were pooled in a random-effects model using STATA 11 (STATA Corporation, College Station, Texas, USA), and assessed for heterogeneity using the I-Squared test.
Table 2
Study selection inclusion/exclusion criteria
Inclusion criteria
Exclusion criteria
P. falciparum malaria
Uncomplicated malaria
Randomized Controlled Trials (observational studies to be considered if no RCT evidence)
IR administration
Children < 5 years old (older children and adult data to be considered if no studies in children)
Diagnosis of severe or complicated malaria, confirmed with microscopy or rapid diagnostic test or cerebral malaria
African setting
IM or IV administration
Table 3
Evidence quality and level of confidence in estimates using the GRADE approach
Evidence Quality
Level of confidence in estimate
High
Further research is very unlikely to change our confidence in the estimate of effect
Moderate
Further research is likely to change our confidence in the estimate of effect, and may change the estimate
Low
Further research is very likely to change the estimate of effect, and is likely to change the estimate
The number of studies identified in the literature search for each question and then the number screened for eligibility and final included studies in the respective systematic reviews are presented in a series of flow diagrams (see Additional File 1).
Systematic review 1: Is there a value in administration of a loading dose of quinine in African children with severe malaria?
One Cochrane systematic review that was a meta-analysis of four African randomized controlled trials was identified [9] (Table 4). Moderate to low quality evidence for critical and important outcomes indicates that a quinine loading dose of 19 to 21 mg/kg may make little or no difference to mortality, coma recovery time, convulsion frequency, asexual parasitaemia at 24 and 48 hours, neurological sequelae or adverse events including hypogylcaemia, hypotension and arrhythmia. However, moderate quality evidence indicates that a loading dose of 20 mg/kg quinine may reduce fever clearance time [Weighted Mean Difference (WMD) 11.11, 95% Confidence Interval (CI) 20.04 to 2.18; n = 68] and parasite clearance time (WMD 7.44, 95% CI 13.24 to 1.64; n = 67) as well as cause temporary hearing loss [Risk Ratio (RR) 3.14, 95% CI 1.05 to 9.38; n = 33] (see Additional File 2).
Table 4
Characteristics of studies that evaluated quinine loading dose (Systematic review 1)
Test quinine sulphate dose (IV)
Comparator quinine sulphate dose (IV)
Study
Age range
Country
Loading dose
Maintenance dose
Uniform dose
Assimadi 2002* (N = 72)
8 months to 15 years
Benin
21 mg/kg
10.5 mg/kg every 12 hours
15.9 mg/kg every 12 hours
Fargier 1991* (N = 20)
15 years and above
Cameroon
19 mg/kg
9.7 mg/kg every 8 hours
9.7 mg/kg every 8 hours
Pasvol 1991# (N = 59)
up to 12 years
Kenya
20 mg/kg
10 mg/kg every 12 hours
5 to 10 mg/kg every 12 hours
Tombe 1992 (N = 33)
14 years and above
Kenya
20 mg/kg
10 mg/kg every 8 hours
10 mg/kg every 8 hours
*Reported quinine doses converted from quinine base to quinine salt using salt conversion factor of 1.21
#N = 20 patients who received IM quinine were excluded from this analysis
Adapted from Lesi et al 2004 Cochrane systematic review [9]
Systematic review 2: Should Kenya change its recommendation for treatment of severe malaria in children under 5 of 15 mg/kg loading dose followed by 10 mg/kg every 12 hours and replace it with the WHO recommended regimen of 20 mg/kg loading dose followed by 10 mg/kg every 8 hours?
There were no head to head comparisons or suitable indirect comparison studies identified in the literature search.
Systematic review 3: What are the pharmacokinetics and effectiveness of IV-administered quinine compared to IM-administered quinine in African children with severe malaria?
Seven studies in African children that evaluated quinine administered with a loading dose by the IV or IM route were identified [10‐16]. In addition, three studies identified by a Cochrane review but on African children not strictly having severe malaria were included [17]. These studies compared the effectiveness of quinine administered with a loading dose by the rectal (IR) and the IV route [18, 19] and the IR and the IM route [20] (Table 5).
Table 5
Characteristics of studies that evaluated effectiveness and pharmacokinetics of quinine by route of administration (IV vs IM or indirect comparison of IR vs IV and IM vs IR) (Systematic review 3)
Study ID
Age range
Country
IV Quinine Dose
IM Quinine Dose
Waller 1990 (N = 21)
19 months to 8 years
Gambia
N/A
20 mg/kg loading dose, then 10 mg/kg every 12 hours
Pasvol 1991‡ (N = 59)
up to 12 years
Kenya
20 mg/kg loading dose, then 10 mg/kg every 12 hours
20 mg/kg loading dose, then 10 mg/kg every 12 hours
Krishna 1991 (N = 120)
1 to 10 years
Ghana
N/A
20 mg/kg loading dose, then 10 mg/kg every 12 hours
Schapira 1993 (N = 104)
6 months to 7 years
Mozambique
20 mg/kg loading dose, then 10 mg/kg every 8 hours
20 mg/kg loading dose, then 10 mg/kg every 8 hours
Winstanley 1993 (N = 22)
7 months to 6.8 years
Kenya
14 mg/kg loading dose, then 10 mg/kg every 12 hours
20 mg/kg loading dose, then 10 mg/kg every 12 hours
Winstanley 1994 (N = 9)
1 to 3 years
Kenya
15 mg/kg loading dose, then 10 mg/kg every 12 hours
N/A
van Hensbroek 1996 (N = 16)
5 to 23 months
The Gambia
20 mg/kg loading dose, then 10 mg/kg every 12 hours
20 mg/kg loading dose, then 10 mg/kg every 12 hours
Study ID
Age
Country
IR Quinine Dose
IV Quinine Dose
Achan 2007† (N = 110)
6 months to 5 years
Uganda
20 mg/kg base loading dose, then 10 mg/kg every 8 hours, until oral treatment possible
8 mg/kg base every 8 hours, until oral treatment possible
Bareness 1998† (N = 77)
2 to 15 years
Niger
11.8 mg/kg base loading dose, then 8.8 mg/kg every 8 hours for 2 days, then oral treatment with chloroquine
4.7 mg/kg base every 8 hours for 2 days, then oral treatment with chloroquine
Study ID
Age range
Country
IR Quinine Dose
IM Quinine Dose
Bareness 2001† (N = 58)
2 to 15 years
Niger
17.9 mg/kg base loading dose, then 11.75 mg/kg base every 12 hours
7.5 mg/kg base every 12 hours
† Quinimax formulation which consists of 96% quinine, 2.5% quinidine, 0.68% cinchonine, and 0.67% cinchonidine
‡N = 21 patients who received a lower dose of IV administered 10 mg/kg loading dose then 5 mg/kg every 12 hours were excluded from the IV vs IM effectiveness analysis only.
Systematic review 3a: What is the effectiveness of IV-administered quinine compared to IM-administered quinine in African children with severe malaria?
Two studies were identified that assessed the comparative effectiveness of quinine route of administration by the IV and IM route when a loading dose of 20 mg/kg was administered, with a maintenance dose of either 10 mg/kg every 12 hours [11] or 10 mg/kg every 8 hours [13]. There was no difference between treatment groups in all the reported outcomes of the individual studies that were all appraised as low quality evidence - risk of death, incidence of neurological sequelae, number of convulsions, coma resolution time, parasite clearance time, fever clearance time, number of hypoglycaemic episodes or haemoglobin levels (see Additional File 3). Further indirect evidence on mortality from 3 studies, deemed to provide very low quality evidence (see Additional File 3), suggested there was no association between risk of death (or any other outcome) and route of administration from the studies that investigated IR quinine vs IV quinine (n = 91 patients) in African children [Odds Ratio (OR) 0.50, 95% CI 0.20 to 1.26; n = 186] [18, 19] (Figure 1) or in one study that investigated IR vs IM quinine (OR 0.15, 95% CI 0.01 to 3.28; n = 58) [20]. Overall, therefore, available evidence is low or very low quality to guide decisions on route of quinine administration with the possibility that clinically important risks or benefits exist, but are not recognized.
Figure 1
Meta analysis of comparison of effect of IR and IV administered quinine on mortality in African children.
×
Anzeige
Systematic review 3b: What is the pharmacokinetics of IV-administered quinine compared to IM-administered quinine in African children with severe malaria?
Four identified studies evaluated the pharmacokinetics of quinine when administered at a loading dose of 20 mg/kg, followed by a maintenance dose of 10 mg/kg every 12 hours [10‐12, 16]. One study evaluated the pharmacokinetics of quinine when administered at a loading dose of 20 mg/kg, followed by a maintenance dose of 10 mg/kg every 8 hours [13]. Very low quality evidence showed that there was no difference in the reported pharmacokinetic parameters of quinine in the individual studies - volume of distribution (Vd), maximum circulating concentration (Cmax), half-life (t1/2), area under the curve (AUC) (Table 6).
Table 6
Pharmacokinetic parameters of IV and IM administered quinine in African children (Systematic review 3b)
Study ID
(sample size)
Evidence
Quality
Route of admn
Sample size per arm
Quinine loading dose
Quinine maintenance dose
Infusion time
Cmax (mg/l)
tmax (h)
t1/2 (h)
Cl (ml/min/kg)
Vd (l/kg)
AUC (mg/l/h)
Pasvol 1991 (N = 43)
Low
IV
n = 21
10 mg/kg
5 mg/kg
2 h
9.7 ± 5.3
2.7 ± 1.3
8.9 ± 4.0
1.36 ± 0.58
0.87 ± 0.27
145 ± 61
Winstanley 1993
(N = 22)
Very
Low
IV
n = 12
14 mg/kg
10 mg/kg bd
2 h
13.8 ± 3.1
-
16.4 ± 8.8
0.45 ± 0.13
0.45 ± 0.10
Winstanley 1994 (N = 9)
Very
Low
IV
n = 9
15 mg/kg
10 mg/kg bd
2 h
17.9 ± 2.9
-
12.6 ± 3.1
0.81 ± 0.24
0.75 ± 0.11
Pasvol 1991 (N = 43)
Low
IV
n = 18
20 mg/kg
10 mg/kg bd
2 h
15.3 ± 5.5
2.4 ± 1.5
12.5 ± 3.2
1.19 ± 0.29
1.22 ± 0.16
254 ± 86
van Hensbroek 1996 (N = 16)
Very
Low
IV
n = 6
20 mg/kg
10 mg/kg bd
4 h
17.48 ± 2.43
-
13.16 ± 6.43
0.51 ± 0.16
1.04 ± 0.21
354 ± 143
Waller 1990 (N = 21)
Very
Low
IM
n = 21
20 mg/kg
10 mg/kg bd
N/A
15.4 ± 4.5
3.23 ± 1.63
18.8 ± 8.0
0.89 ± 0.81
-
449 ± 243
Pasvol 1991 (N = 43)
Low
IM
n = 20
20 mg/kg
10 mg/kg bd
N/A
15.3 ± 7.6
2.4 ± 1.7
15.7 ± 8.2
1.12 ± 0.56
1.22 ± 0.32
332 ± 254
Winstanley 1993 (N = 22)
Very
Low
IM
n = 10
20 mg/kg
10 mg/kg bd
N/A
15.7 ± 3.1
1.6 ± 1.7
-
-
-
-
van Hensbroek 1996 (N = 16)
Very
Low
IM
n = 10
20 mg/kg
10 mg/kg bd
N/A
16.36 ± 3.67
1.08 ± 0.37
15.31 ± 7.16
0.59 ± 0.25
1.32 ± 0.49
358 ± 164
Krishna 2001 (N = 120)
Very
Low
IM
n = 120
20 mg/kg
10 mg/kg bd
N/A
-
-
19.9 ± 4.4
0.05
-
-
Legend:
Cmax (mg/l): Maximum circulating concentration
tmax (h): Time at maximum circulating concentration
t1/2 (h): Half-life
Cl (ml/min/kg): Clearance
Vd (l/kg): Volume of distribution
AUC (mg/l/h): Area under the curve.
Systematic review 4: Is there a link between IV-administered quinine and risk of hypoglycaemia in African children with severe malaria?
Six studies that evaluated the risk of hypoglycaemia in the population and setting of interest to this review were identified [2, 21‐25] (Table 7). Of these, five studies [21‐25] found no effect of IV quinine when given at a slow infusion rate on the number of hypoglycaemic episodes or insulin levels in the children. An association with hypoglycaemia was observed in children, however, when quinine was administered at a high infusion rate. Overall quality of evidence was rated as low or very low to inform decisions on alternative quinine regimens. Recently published high quality evidence, which evaluated the effectiveness of quinine and the artemisinin derivative artesunate in African children up to 15 years of age, however, found 2.8% of patients treated with quinine developed hypoglycaemic episodes, with artesunate treatment associated with a significantly lower risk (OR 0.63, 95% CI 0.43 to 0.91; n = 5,425) [2] (see Additional File 4).
Table 7
Characteristics of studies that evaluated risk of hypoglyacemia with IV-infused quinine (Systematic review 4)
Study ID
Evidence quality
Age range
Country
IV Quinine Dose and diluent
Infusion time
Infusion rate (ml/kg/24 h)
Glucose Threshold (mmol/l)
Molyneux 1989
(N = 29)
Very low
2 to 9 years
Malawi
10 mg/kg in 5% glucose in half strength Darrow's solution
1 h
80
< 2.2
10 mg/kg in 5% glucose in half strength Darrow's solution
3 h
80
< 2.2
20 mg/kg in 5% glucose in half strength Darrow's solution
3 h
80
< 2.2
Okitolonda 1987
(N = 9)*
Very low
6 to 10 years
Zaïre
10 mg/kg in 30 ml saline supplemented with 2.5% glucose every 8 hours
1 h
105
< 2.8
Kawo 1991
(N = 97)
Very low
Up to 7 years
Tanzania
10 mg/kg in 10 ml/kg of 5% glucose every 8 hours
4 h
Not reported
< 2.2
Ogetii 2010
(N = 1237)
Low
Up to 12 years
Kenya
15 mg/kg loading dose in 5% dextrose then 10 mg/kg in 5% dextrose every 12 hours
2 h
Not reported
< 3, < 2.8 and < 2.2
20 mg/kg loading dose in 5% dextrose then 10 mg/kg in 5% dextrose every 8 hours
4 h
Not reported
< 3, < 2.8 and < 2.2
Taylor 1988
(N = 95)
Very low
7 months to 8 years
Malawi
20 mg/kg loading dose then 10 mg/kg every 8 hours
Loading dose 4 h,
then maintenance dose 2 to 8 h
80
< 2.2
Dondorp 2010
High
Up to 15 years
Multi-centre trial in Mozambique, The Gambia, Ghana, Kenya, Tanzania, Nigeria, Uganda, Rwanda and Democratic Republic of Congo
¥20 mg/kg loading dose in 5-10 ml/kg of 5% dextrose then 10 mg/kg in 5-10 ml/kg of 5% dextrose every 8 hours
Loading dose 4 h,
then maintenance dose 2 to 8 h
Not reported
Not reported
*Data from N = 5 adults were excluded from this analysis
Ogetti 2010 = Retrospective review of case notes. ¥Quinine was administered by the IM and IV route.
Discussion
The WHO malaria treatment guidelines updated in 2010 have introduced the appraisal of studies using the GRADE tool but only for newly acquired evidence since the 2006 guidelines. Of relevance to severe malaria, this encompassed only one topic, the comparison of safety and effectiveness of quinine and artemisinin derivatives in treating severe malaria, with reviews conducted before the recently published large trial on artesunate [2]. Other topics in the WHO 2010 guidance of (i) loading dose of quinine (20 mg/kg) vs. no loading dose, (ii) effectiveness of IM vs IM quinine, (iii) IM artemether vs IV quinine and (iv) safety and efficacy of pre-referral treatment with IR artesunate were reported as narrative summaries of the evidence only, with no transparent assessment or grading of recommendations. Although the new data indicating the superiority of artesunate compared with quinine (see Additional File 5) [2] will change the landscape for guidelines, many African countries are likely to continue to rely on quinine therapy for severe malaria in children for some years to come. Quinine has well known, serious adverse effects and previous and current WHO recommendations (2010) have not used systematic approaches when attempting to appraise the evidence to guide dosing.
Despite more than 30 years of clinical use, only studies of important (not critical) outcomes and only very low or low quality evidence are available to inform most paediatric quinine dosing decisions. Thus, there are no data directly comparing the Kenyan regimen of the last 12 years and only limited data suggesting either the IV or IM routes may be used, although IM quinine is mainly recommended for pre-referral treatment due to the risks of developing an IM injection abscess and other complications when incorrectly administered (Personal Communication, Dr Elizabeth Juma, Head of Division of Malaria Control, Ministry of Public Health and Sanitation). Very limited data also suggest that hypoglycaemia is more likely with faster rates of administration. Only in the case of the use of a loading dose is there moderate quality evidence to guide recommendations, but only for what was considered as non-critical outcomes. These included reduced fever and parasite clearance time with loading doses, but also higher risks of transient hearing loss with higher loading doses [9].
Anzeige
This work thus indicates, historically, how the Kenyan policy on quinine dosing that has been promoted nation-wide for over 10 years, with considerable investments in dissemination of guidelines and in-service training supported by global funds, was based predominantly on low or very low quality evidence by today's standards. The available very low quality evidence does however suggest similar pharmacokinetic parameters for the lower dose Kenyan regimen as the currently recommended WHO regimen. The fact that the 2010 WHO quinine dosing regimens (that are unchanged) are also based on low quality evidence, even for safety, does not provide an obvious rationale for Kenya's change to adopt the WHO guidance. While it is considered entirely appropriate that other factors are considered in making recommendations based on evidence [3, 26], this process is rarely transparent, as is the case with Kenya's change of its quinine regimen.
The emergent message from the series of systematic reviews we conducted is the paucity of high quality evidence that may inform the dose, route of administration and safety of treatment of African children diagnosed with severe malaria with quinine, notwithstanding that quinine has been the standard treatment of severe malaria for decades (Table 8). This contrasts starkly with the evidence available to inform policy for children with non-severe malaria. Here international efforts and funding have supported over fifty randomized controlled trials in recent years [27]. Despite huge investments to tackle malaria over the last decade or more [28] it is clear therefore that severe malaria in African children has remained a neglected disease. In conducting these systematic reviews we found the GRADE approach a very useful tool for making the presence of only low quality evidence explicit. This paper postulates that the wider use of this or other similar approaches can help build advocacy efforts for a greater research focus on priority areas in paediatric therapeutics in African and other low-income settings.
Table 8
Summary of quinine systematic reviews in the treatment of severe malaria in African children and recommendations for evidence-informed clinical practice
Clinical Issue
Recommendation
Evidence quality/strength of recommendation
Systematic review 1: Is there a value in administration of a loading dose of quinine in African children with severe malaria?
Loading dose results in faster clearance of malaria parasites from the blood stream and thus faster clearance of fever and thus loading dose should be administered, with monitoring and patient/care giver support for episodes of partial hearing loss adverse event
Moderate
Systematic review 3a: What is the effectiveness of IV-administered quinine compared to IM-administered quinine in African children with severe malaria
Quinine route of administration: IV vs IM [11, 13, 18‐20]
The clinical outcome of IV-administered quinine vs. IM-administered quinine is equivocal in the treatment of African children with severe malaria. However, due to reported side effects with IM route, such as risk of abscess and pain, the IV route is preferred.
Low to very low
Systematic review 3b: What is the pharmacokinetics of IV-administered quinine compared to IM-administered quinine in African children with severe malaria
The risk of hypoglycaemia with quinine treatment in African children with severe malaria may be countered by administering the quinine at a low infusion rate.
Glucose levels should be monitored due to hypoglycaemic risk that occurs due to the disease and/or quinine treatment, and should be treated with glucose infusion
Artesunate is a superior treatment to quinine for African children with severe malaria and should be strongly considered for implementation as a first line treatment, taking contextual factors such as cost-effectiveness into account
High
The recent findings of the large multicentre trial demonstrating superiority of artesunate over quinine for severe malaria in African children [2] provide a clear argument for a change in approach on the continent. These data demonstrate how poor the foundational basis was for the use of quinine and should help argue that the practical difficulties of introducing artesunate should be overcome as soon as possible. Further, this work supports that efforts to introduce explicit methods of examining the evidence base for treatment of children in low-income settings should be strongly supported.
Acknowledgements
NM is funded by ME's Wellcome Trust Senior Fellowship (#076827).
Anzeige
NO is funded by a Wellcome Trust Strategic Award (#084538).
ME is funded by a Wellcome Trust Senior Fellowship (#076827).
NM acknowledges statistical advice from Ms Tansy Edwards and Dr John Wagai.
The authors acknowledge useful discussions with Dr Andrew Nyandigisi and Dr Dorothy Naisiae of the Division of Malaria Control, Ministry of Public Health & Sanitation. This paper is published with the permission of the director of KEMRI.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ME conceived of the topics for the systematic reviews. NM developed the methodology and conducted the reviews with assistance from NO. NM drafted the manuscript and ME and NO contributed to it. All authors read and approved the final manuscript.
